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ABSTRACT
Prostaglandin F2α is commonly administered to manipulate the estrous cycle in mares, at
a dosage of dinoprost tromethamine (Lutalyse®) at 10 mg, administered IM. My
objectives were to compare three serial low-dose PGF2α protocols, and determine the
most effective treatment in terms of number of injections, intensity of protocol, time
allocated, and labor. Quarter Horse mares (n=11) were used in a crossover design.
Lutalyse was administered at 1.1 mL per injection: treatment 1- PGF2α once 6d postovulation; treatment 2- PGF2α twice daily 0 d, 1 d, and 2 d, then once 3 d and 4 d postovulation; treatment 3- PGF2α twice daily on 2 d, then once 3 d and 4 d post- ovulation.
Teasing scores were assigned daily. Rectal palpation and ultrasound were performed to
measure follicular growth and detect ovulation. Blood samples were drawn on 3 d and 6 d
post-ovulation to analyze plasma progesterone (P4) levels. One-way ANOVA and Tukey
Method Pairwise Comparisons were used for data analysis. Between treatments on 3 d
and 6 d post-ovulation, plasma P4 values were not statistically different. Mean intervals
from ovulation to ovulation for treatments 1, 2, and 3 were 14.8 d ± 3.1, 12.9 d ± 6.3 d
and 14.3 d ± 1.4 respectively. Mean intervals from first day of treatment to ovulation
were 9.8 d ± 2.0, 12.9 d ± 6.3, and 12.6 d ±1.7. Results did not show significant statistical
difference. Further research is needed on low-dose administration of PGF2α.
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INTRODUCTION

Justification of the Study
The equine industry in the United States has an economic impact of
approximately $102 billion, a number recorded in 2005 and since increasing. With over
1.4 million full-time jobs supported by the equine industry and over 9 million horses in
the United States, the equine industry is a diverse and powerful substructure of the
American economy (American Horse Council, 2017).
Manipulation and control of the estrous cycle of mares is critical to the prosperity
and vitality of the equine industry. Implemented estrous and ovulation synchronization
protocols allow industry professionals to coordinate and allocate time, money, and
resources to maximize success during the breeding season, and ultimately pregnancy
rates in mares.
When estrus and ovulations are synchronized, artificial insemination practices can
be managed, or natural breeding can be planned efficiently for maximization of each
stallion. Estrous synchronization allows embryo transfer and cloning processes to come
to fruition with as little disturbance as possible (Klug and Jöchle, 2001).
Administration of Prostaglandin F2α (PGF2α) is reportedly the most common
method of estrus synchronization in the mare (Coffman and Pinto, 2016). Clinical uses of
PGF2α include estrous synchronization, treatment for persistent CL syndrome, shortcycling, and the termination of unwanted pregnancies (Burden et al., 2015). In the
1970’s, research identified PGF2α as an endogenous luteolysin. The administration of
exogenous PGF2α is widely accepted as an effective method of inducing luteolysis in
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order to synchronize the estrous cycle (Coffman and Pinto, 2016). The induction of
luteolysis is critical to the success of the reproductive management of the mare (Kuhl et
al., 2016a).
A more comprehensive understanding of the effects of various dosage protocols
of exogenous prostaglandin given to cycling mares will allow advancement and success
in regards to reproductive success of the mare.

Statement of Purpose and Objectives of the Study
The purpose of this study was to determine if a new treatment protocol would
hasten the return to estrus and ovulation in cycling mares. Three serial low-dose PGF2α
treatment protocols were compared in terms of total injections and intensity of protocol,
in relation to efficacy of treatment. Results from this study may provide insight into lowdose hormonal manipulation of the estrous cycle, to be implemented into new breeding
management practices.
The objective of the study was to determine the efficacy of serial low-dose
administration of PGF2α designed to prevent luteal development and shorten the interval
to ovulation in cycling mares.

Hypotheses
This study was designed around two hypotheses, as follows:
1. Low-dose serial administration of PGF2α will not be as effective at inducing
luteolysis and shortening the intraovulatory period or preventing development of
the CL as the standard dosage rate for dinoprost tromethamine (Lutalyse®) in
mares.
2. There will be no difference in efficacy between treatment protocols.
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LITERATURE REVIEW

Overview of the Estrous Cycle
Cyclicity of the mare is characterized by seasonal polyestrous; there are periods
during the year in which most mares do not cycle regularly. Mares are long-day breeders,
becoming the most reproductively receptive in the spring and into the summer (Senger,
2012). Regulation of gonadotropin releasing hormone (GnRH) secretion is dependent on
photoperiod. When the photoperiod is short, the pineal gland secretes melatonin, which
downregulates GnRH production in the hypothalamus. When the photoperiod increases,
melatonin production decreases, allowing GnRH to stimulate the release of FSH and LH.
(Blanchard et al., 2003).
Research has suggested that leptin and kisspeptin may have a direct effect on
GnRH neurons in the hypothalamus. Adipocytes secrete leptin, a hormonal peptide, in
relation to the fat content in the body. Leptin may be critical to the hypothalamic
signaling that the animal is at an acceptable nutritional status for reproductive
performance. Additionally, kisspeptin signaling supplies GnRH cell bodies in the
hypothalamus. In response to leptin, kisspeptin neuron activity may be stimulated, which
in turn stimulated GnRH neurons (Senger, 2012).
Gonadotropin releasing hormone is secreted in the hypothalamus and released
into the hypothalamic-pituitary portal system. In the anterior pituitary, GnRH then
stimulates the production and secretion of follicle-stimulating hormone (FSH) and
luteinizing hormone (LH). When estrogen is high and progesterone is low, LH secretion
increases. Progesterone (P4) levels increase in the luteal phase as the CL continues to
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develop. Once progesterone levels are above 2 ng/mL, behavioral signs of estrus are not
seen in most mares. Ovulation is typically characterized by signs of estrus and plasma
progesterone concentrations measuring 1 ng/mL or less. However, ovulation can occur
without estrus, referred to as silent heat; low P4 levels allow the subsequent surge of LH
and thus ovulation. The largest follicle is normally the one to ovulate; complete ovulation
occurs in 2 to 7 minutes following the onset (Blanchard et al., 2003).
The average estrous cycle of the mare is 21 days long. Estrus typically lasts 7
days in mares. After the onset of estrus, ovulation occurs in approximately 5 days. After
the LH surge, ovulation should be expected within 2 days (Senger, 2012). The estrous
cycle is characterized by two distinct phases- the follicular phase and the luteal phase.
The follicular phase occurs from the time the CL regresses, to the time of ovulation.
Large antral follicles develop during the follicular phase, one of which will become
dominant and later ovulate. Estradiol is secreted by the follicles, and is highest during the
follicular phase. During the luteal phase, the CL develops, which creates an increase in
progesterone levels. Follicular growth and development occurs during proestrus, along
with secretion of estradiol. During estrus, estradiol secretion reaches its peak, and the
mare becomes sexually receptive to the male. Progesterone secretion begins during
metestrus, as CL formation begins, and progesterone secretion is then sustained during
the diestrus period of the estrous cycle (Mottershead 2001; Figures 1 and 2).
During the estrous cycle, follicular development occurs in a wave-like pattern.
Several large follicles develop during a major follicular wave; one follicle will continue
growth as the dominant follicle while smaller follicles will undergo atresia. The dominant
follicle secretes hormones which inhibit FSH, which in turn halts growth of the non-
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dominant follicles (Shirazi et al., 2002). Proestrus and estrus both occur during the
follicular phase of the estrous cycle, while metestrus and diestrus both occur during the
luteal phase of the estrous cycle. The follicular phase accounts for approximately 20% of
the estrous cycle. In turn, 80% of the estrous cycle is the luteal phase (Senger, 2012).

Biochemistry of Progesterone
Progesterone is a steroid hormone synthesized from cholesterol. Cholesterol can
either be synthesized in the smooth endoplasmic reticulum via de novo synthesis, or
synthesized in the liver from acetate and released into the bloodstream in lipid droplets.
Pregnenolone, a 21-carbon intermediate, is produced via side-chain hydrolysis of
cholesterol. 3ß-hydroxy-∆5-steroid dehydrogenase then converts pregnenolone to
progesterone. Progesterone can later be converted to estrogens, androgens, or
corticosteroids (McKinnon and Voss, 1993).
Thecal cells produce 3ß-hydroxy-∆5-steroid dehydrogenase needed for the
conversion of pregnenolone to progesterone; progesterone can then be converted to
estradiol in the granulosa cells (Rotstein, 2016). The CL is the primary location of
progesterone secretion (McKinnon and Voss, 1993). See Figure 3 for an overview in
changes of plasma progesterone concentrations throughout the estrous cycle.

Biochemistry of Prostaglandins
Eicosanoids act at low concentrations, and are critical to reproduction.
Eicosanoids do not transport through the bloodstream to their target tissue, but tend to act
closer to the cells of production (Voet et al., 1999). Prostaglandins are classified as
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eicosanoids, comprised of modified long-chain fatty acids with 20 carbon atoms.
Prostaglandin synthases are used in the cyclooxygenase pathway to synthesize
prostaglandins from arachidonic acid, which becomes available when phospholipids of
the cell membrane are hydrolyzed. The phospholipid degradation is quickened in the
presence of phospholipase A, which serves a catalytic role (Coffman and Pinto, 2016).
PGF2α stimulates cyclooxygenase (COX)-2 mRNA expression in not only epithelial cells,
but also in stromal cells. Low dose administration of PGF2α can increase COX-2
expression, in turn inducing luteolysis. The increase in COX-2 expression leads to autoamplification of endometrial PGF2α production (Okuda et al., 2014).
Prostaglandin F2α and prostaglandin E2 (PGE2) are the two main prostaglandins
associated with reproduction in the mare. Endogenous prostaglandins are not only
metabolized in the target tissue, but also in the lungs, kidneys, and liver. In mares, PGF2
is metabolized to 15-keto- PGF2α, then 13,14-dihydro-15-keto- PGF2α, then 11ketotetranor-PGF compounds. The 13,14-dihydro-15-keto metabolite is more stable when
separated from red blood cells in either plasma or serum, despite its 5 minute half-life.
Therefore, prostaglandin F2α metabolite (PGFM) concentrations can be measured from
peripheral blood in order to estimate the amount and rate that PGF2α is released from
tissues at (McKinnon and Voss, 1993).

Role of Prostaglandin in the Estrous Cycle
Prostaglandin F2α is known as the main luteolysin, which is secreted from the
endometrium. Prostaglandin F2α and progesterone metabolite concentrations can be
measured by enzyme immunoassay profiles. When cloprostenol treatment effect on
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cycling mares was analyzed, no cross reaction between progesterone and PGFM was
demonstrated. Two hours post-treatment, progesterone decreased 50% and by 90% 24
hours post-treatment. An increase in PGFM peaked at 45 minutes post-treatment, then
decreased before again increasing at 16 hours post-treatment to the same level as the 45
minute post-treatment level (Okuda et al., 2014). Studies have shown that the ovulatory
effect of PGF2α not only occurs at the follicular level, but also in the central nervous
system at the hypothalamus-hypophysis axis. Following PGF2α administration, FSH and
LH levels in peripheral blood increase followed by an increase in GnRH (Newcombe et
al., 2008).
During luteolysis, oxytocin may be the main inductor of pulsatile secretions of
PGF2α from the uterus. Prostaglandins are synthesized actively in the equine CL and may
serve a critical role in its auto-paracrine regulation (Lukasik et al., 2014). Concentrations
PGF2α and PGE2 were recording throughout the luteal phase, as well as mRNA
transcription of PG synthesis enzymes found in the equine CL. Plasma progesterone
levels, follicular diameter, and morphological appearance of the CL were all used to
classify luteal structures. PGF2α and PGE2 levels were lowest in the mid-development of
the CL (P<0.05), and the highest during the early-development CL (P<0.05).
Prostaglandin-endoperoxide synthase 2 (PTGS-2) and synthase prostaglandin E (PGES)
synthesis via mRNA transcription were measured highest in the early-development CL
(P<0.05). In a second experiment, PGF2α and PGE2 stimulated mRNA transcription of
PTGS-2, PGES, OXT receptor (OXTR), and 3ß-hydroxysteroid dehydrogenase (3βHSD)
enzymes, while simultaneously stimulating progesterone and oxytocin secretion (P<0.05)
(Lukasik et al., 2014).
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Administration of PGF2α
During the 1970’s and 1980’s, various PGF2α analogues were tested and
developed for potential use in the livestock industry. Prostalene and fenprostalene, alphachain allenic analogs, as well as fluprostenol were developed; fluprostenol being a
synthetic PGF2α analog similar to cloprostenol. Luprostiol, a synthetic PGF2α analogue, is
not approved for use in the United States but is available in certain European countries
(Coffman and Pinto, 2016).
Dinoprost tromethamine, the natural analogue of PGF2α, is the only form of PGF2α
that has received approval by the FDA in the United States (Lutalyse; Pfizer Animal
Health). Dinoprost tromethamine is a tham salt; naturally occurring in the PGF2α
molecule. 1.34 mg of dinoprost is equal to 1 mg of PGF2α free acid. The labeled dosage
of dinoprost is 10 mg per mare, although studies have shown significantly smaller doses
to have high efficacy rates as well. A single injection of 1.25 mg dinoprost can be
effective when administered between days 6 and 12 following ovulation. Lutalyse is
diluted to 5 mg/mL, therefore administration does not require dilution. Doses as low as
1.1 ug/kg have been reported as having an affect on luteal function, but this dose may not
result in complete luteolysis. After administration of 5 mg PGF2α IV, plasma clearance
was 3.3 ± 0.5 L/hr/kg, half- life was 1.57 ± 0.26 minutes, elimination half- life was 25.9 ±
5.0 minutes, and maximum plasma PGF2α concentration was 249.1 ± 36.8 ng/mL
(Coffman and Pinto, 2016).
Closprostenol is a synthetic analogue of PGF2α which is commonly used by
industry professionals to shorten the interval to ovulation, due to its longer half-life than
dinoprost. Additionally, there are fewer side effects associated with cloprostenol. The
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pharmokinetic parameters of cloprostenol in horses have not been published. There are
two enantiomers of cloprostenol available; d-cloprostenol and l-cloprostenol.
Recommended dosage rates for cloprostenol are noticeably smaller than the
recommended dosage rates of dinoprost. The d-enantiomer is pharmacologically active
and luteolytic, therefore the dosage needed to induce luteolysis is much lower than the
luteolytic dose of d,l-cloprostenol. Estrumate, produced by Merck Animal Health, is a
commonly used racemic mixture of d,l-cloprostenol sodium administered at a dosage rate
of 250 to 500 µg per mare. In other countries, the active d-cloprostenol enantiomer is
used in order to prepare stronger solutions of cloprostenol, though not available in the
United States (Coffman and Pinto, 2016).
To shorten the luteal phase of the estrous cycle, PGF2α can be administered
subcutaneously or intramuscularly to induce luteolysis. Mares treated with PGF2α
typically display estrus anywhere from 2 to 5 days post-treatment, and ovulate 7 to 10
days post-treatment. However, if a large follicle is present at the time of PGF2α
administration, mares may ovulate as soon as 48-72 hours following treatment with
PGF2α (Coffman and Pinto, 2016). In mares with a confirmed fully functional CL, PGF2α
has approximately an 80% luteolytic rate when given as a single dose to mares 5 days
post-ovulation. Following PGF2α treatment, progesterone levels decrease drastically, and
the CL undergoes lysis. Endometrial edema will develop, and the interovulatory interval
will also decrease. The interovulatory interval is also decreased when partial luteolysis
occurs. However, no endometrial edema will develop, which may increase the incidence
of silent heat (Newcome and Cuervo-Arango, 2014).

9

If an atretic or small preovulatory follicle is present at the time of PGF2α
treatment, the interval from treatment to ovulation may be as long as 15 days. A single
dose of PGF2α given during the early (0-4 days post-ovulation) diestrus period did not
induce luteolysis. Following the trials, the conclusion was drawn that the equine CL is
not fully responsive to the luteolytic actions of PGF2α until the CL is, at minimum, 5 days
old (Coffman and Pinto, 2016).
Cloprostenol can decrease the time needed for follicular maturation, lysis of the
CL, and ovulation in mares. Efficacy of treatment was dependent on the dose of
cloprostenol administered. For each treatment group, the interval to ovulation decreased
as the size of the pre-ovulatory follicle at time of treatment increased. A synergistic
relationship was present between follicular diameter and dose efficacy (Newcombe et al.,
2008). The dose of cloprostenol administered to each mare effects the interval to
ovulation; hence the use of cloprostenol may be a method of more precisely controlling
the estrous cycle, as well as the time of ovulation, in the mare (Newcombe et al., 2008).
When compared to cloprostenol, a larger number of mares ovulated within 48
hours of hCG administration when given luprostiol (P<0.01). Additionally, mares given
luprostiol displayed a shorter interval from hCG treatment to ovulation (P<0.01).
However, no difference was shown in the interval from estrus to hCG treatment, or the
interval from estrus to ovulation. Preovulatory follicles in both treatment groups
measured smaller at the time ovulation was induced when compared to the control group
(Kuhl et al., 2016a).
The rate of double ovulations was not significantly impacted in mares treated with
either luprostiol or cloprostenol. Furthermore, fertility and pregnancy rates were not
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affected by administration of PGF2α analogs luprostiol or cloprostenol. In 2016, the
interval from PGF2α administration to ovulation showed less variation using luprostiol
rather than cloprostenol, when given to mares in the luteal phase of the estrous cycle
(Kuhl et al., 2016a).
When PGF2α was given in the early post-ovulatory period, luteal function was
inhibited, due to low levels of plasma progesterone. Inhibition of luteal function should
induce the return to estrus and ovulation, followed by a normal diestrus period of the
estrous cycle. Subsequently, mares treated with PGF2α during the study were expected to
conceive at normal fertility rates when artificially inseminated following treatment.
PGF2α is an efficient way of inhibiting luteal function, or promoting anti-luteogenesis. In
this study, no effect of PGF2α treatment on fertility rate was found in the estrus period
following treatment (Pinto et al., 2014).
When administered to mares with a 28 mm or larger follicle, ovulation may occur
in less than 4 days; concerns have surfaced that PGF2α may alter the fertility of those
manipulated cycles. When evaluating the effect of the interval from PGF2α treatment to
ovulation on embryo recovery rates, as well as pregnancy rates in mares, the interval
from treatment to ovulation (ITO) was found to have a significant (P=0.01) effect on the
embryo recovery rate (ERR) in the mares, with the highest ERR recorded for the mares
with an ITO of 6 to 10 days. Additionally, the ERR in mares with an ITO of less than 6
days was reduced, when compared to the ERR of mares with a longer ITO. In this study,
no association was found between ITO and pregnancy rate (Pietrani et al., 2016).
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PGF2α Synchronization Protocols
As reviewed by Coffman and Pinto (2016), Douglas and Ginther conducted an
early study, with mares administered either 1.25, 2.5, 5.0, or 10.0 mg of PGF2α
intramuscularly (IM) 6 days after ovulation. All mares displayed shorter diestrus and
interovulatory intervals, when compared to control mares that were not treated with
PGF2α. In subsequent trials, some mares underwent complete luteolysis 3 days after
ovulation, though this is not a reliable measure of the efficacy of synchronization
utilizing PGF2α injections. Recommendations to administer PGF2α 5 days after ovulation
were implemented following the study. When the date of ovulation is unknown, PGF2α
treatments should be repeated for 2-3 days to minimize the risk of CL resurgence
(Coffman and Pinto, 2016).
In 1974, research revealed the ability of PGF2α to induce partial luteolysis,
followed by a subsequent resurgence of a functional CL. Two mares were given a low
dose of PGF2α 9 days after ovulation, with plasma progesterone decreasing approximately
12 hours post-treatment. However, a rise in progesterone levels was noted at 48 hours
post-treatment (Coffman and Pinto, 2016). In a 2014 study, mares given between 4 and
13 treatments of PGF2α at a dosage rate of 37.5 µg of d-cloprostenol per injection
displayed a significant decrease in the percentage of mares which underwent full
luteolysis (P<0.01). Data analysis suggested that the number of treatments received, as
well as the length of treatment could both factor into the decreased luteolytic response in
the mares. PGF2α receptors on the CL may be physiologically inclined to abnormal
luteolysis when under the influence of more intensive PGF2α treatment plans. Following
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treatment, the number of mares with a longer diestrus period also increased (Newcombe
and Cuervo-Arango, 2014).
A common assumption in the equine breeding industry is that the early CL is not
responsive to luteolytic actions of PGF2α administration. Repeated PGF2α treatment
during the early diestrus period may produce a similar return to estrus to those mares
administered a single PGF2α injection during the mid-diestrus period of the estrous cycle.
Additionally, fertility of the early diestrus induced mares was hypothesized by Coffman
et al. (2014) to not differ from those mares treated conventionally with one injection. In
group 1, mares were given a single 10 mg (2.0 mL) dose of dinoprost tromethamine on
day 10 post-ovulation. In group 2, mares were administered 10 mg PGF2α twice daily on
days 0, 1, and 2, then given 10 mg PGF2α once daily on days 3 and 4 post-ovulation.
Once a 35 mm or larger follicle was detected, mares in estrus were artificially
inseminated with a minimum insemination dose of 2 billion motile sperm. Pregnancy was
then determined after a growing embryonic vesicle was detected on 2 consecutive
examinations, 14 days post-ovulation (Coffman et al., 2014).
In group 1 mares, Coffman et al. (2014) concluded that luteolysis occurred within
48 hours of treatment. When PGF2α is administered at a higher frequency during early
diestrus, the antiluteogenic effects are similar to those seen when a single injection is
given in the mid-diestrus period of the cycle. In group 2, the treatments given on days 3
and 4 prevented luteal resurgence and prolonged luteal formation, in turn increasing the
response rate of the treatment group. Luteal cells are responsive to PGF2α, almost
immediately following ovulation. The diestrus period of the cycle was shortened for
mares administered PGF2α in both the early and mid-diestrus phases of the estrous cycle.
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PGF2α administration during early diestrus provided a shorter interval to ovulation when
compared to the mares given PGF2α during the mid-luteal phase (Coffman et al., 2014).

Synchronization of Estrus in Other Livestock Species
The ovarian anatomy of the mare displays distinct differences from the bovine
ovarian anatomy. The cortex and medulla of the ovary are reverse of what is seen in
cattle; the cortex is located inside the ovary. While ovulation occurs from various
locations of the bovine CL, ovulation only occurs at the ovulation fossa in the mare.
Additionally when rectal palpation is performed in the mare, follicles may be palpated
but the CL is not easily palpated manually because of its location in the ovarian medulla
(Senger 2012).
The equine CL is 18-fold more sensitive to PGF2α than the bovine CL. The equine
luteal cell membrane has a 10-time greater affinity for PGF2α when compared to the
bovine cell membrane. The higher sensitivity of the equine CL to PGF2α may be
attributed to the strong binding affinity of PGF2α to the CL, as well as the slower
metabolic passage rate in mares (Coffman and Pinto, 2016). In cattle, PGF2α metabolite
peaks are followed by an increase in progesterone concentrations every 8 hours.
Progesterone will increase until reaching the pre- PGFM pulse concentration (Ginther
and Santos, 2015).
In cattle treated with a PGF2α analog, nitric oxide metabolites may be detected in
an ovarian vein sooner than detected in a jugular vein. Because of the earlier detection in
the ovarian vein, changes in the systemic concentration of nitric oxide metabolites can be
utilized in order to identify nitric oxide production changes in the ovary. Research in
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heifers has suggested that LH is critical for the systemic increase in nitric oxide
metabolites, which is associated with a simulated PGFM pulse (Ginther et al., 2015).
Similar to what has been done with cattle and sheep, nitric oxide metabolite
plasma concentrations were collected from equine jugular veins in order to measure nitric
oxide metabolite output. The measured changes in jugular plasma nitric oxide metabolite
concentration were, in this study, associated with a PGFM pulse, although only at a
certain stage of luteolysis. Although this study did not find the CL to be the primary
source of nitric oxide production, nitric oxide production during luteolysis may be
analyzed by researching the nitric oxide metabolite concentration within the general
circulation of the equine system (Ginther et al., 2015).

Anovulatory Follicles
Hormonal treatment with PGF2α may increase the risk of either double ovulations
or anovulatory follicles. In order to determine the frequency of double ovulations and
anovulatory follicles occurring in cycling mares treated with PGF2α, mares were given 5
mg PGF2α at 10 days post-ovulation. Transrectal ultrasounds were performed every 2
days until a 25 mm follicle was detected, then once every day until determination of
ovulation. Double ovulations occurred in 15% more cycles within the treatment group
when compared to the control group, which was not treated with PGF2α. The frequency of
either a double ovulation or a single ovulation in concurrence with an anovulatory follicle
was 6 times greater in the treatment group when compared to the control. (Ginther and
Al-Mamun, 2009).
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The occurrence of hemorrhagic anovulatory follicles following cloprostenol
administration has been evaluated for its impact on the interval to ovulation in mares
(Burden et al., 2015). Mares in the study were given a single IM injection of 250 μg
cloprostenol, at varying times between days 5 and 12 post-ovulation. The average interval
from treatment to ovulation recorded for the study was 8.4 + 2.5 days (P < 0.05). An
inverse relationship between the interval from treatment to ovulation and the diameter of
the largest follicle at time of treatment was observed. Three different treatment outcomes
were observed: ovulation within 48 hours post-treatment (13.4%) with varying levels of
uterine edema, ovulation after 48 hours post-treatment (73.1%) with larger uterine edema,
or follicular regression without ovulation (13.4%), with a new dominant follicle
eventually developing. Both age of the mare as well as season had no effect on the
interval from treatment to ovulation. Development of hemorrhagic anovulatory follicles
was low overall, at 2.5% (Burden et al., 2015).
Uterine pathology and decreased PGF2α production can both contribute to
persistent CL syndrome. Spontaneous or idiopathic persistent CL syndrome may also
occur with normal uterine pathology. Persistent CL Syndrome progesterone
concentrations are similar to the levels observed before the CL resurgence that occurs
during pregnancy, with the concentration remaining constant approximately halfway
between the levels recorded at day 8 and the end of luteolysis (Ginther and Santos, 2015).
Eighty-five percent of anovulatory follicles in mares are hemorrhagic; the
likelihood of anovulatory follicles may increase with age of mare as well as hormonal
manipulation of the estrous cycle (Cuervo-Arango et al., 2009). When hemorrhagic
anovulatory follicles are present, bleeding into the lumen of the dominant follicle occurs,
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which is typically followed by eventual luteinization. Because of the anticoagulant
factors found in equine follicular fluid, the blood does not clot as quickly. Once clotting
begins, granulosa and theca cells enter the lumen, multiply, and then luteinize; in turn
producing the luteinized anovulatory follicle which is responsible for progesterone
production (Burden et al., 2015).
A reported 15% of anovulatory follicles develop atresia, or become persistent
anovulatory follicles. No significant hemorrhage occurs in the follicular lumen; the
follicle does not luteinize and in turn does not produce progesterone (Burden et al.,
2015). Hemorrhagic anovulatory follicle formation may differ between studies as
influenced by: breed of mares used, number of mares involved in the study, location of
the experiment, timing and dosage of PGF2α treatments, as well as the extensity of
reproductive management involved in the study (Burden et al., 2015).
Following PGF2α treatment and subsequent luteolysis, a decrease in progesterone
leads to an increase in LH at an earlier phase of follicular development, which may
increase the probability of hemorrhagic anovulatory follicle development. Follicular
growth and ovulation were not disrupted by increased and premature exposure to LH
while fluid factors were altered, which could lead to lapses in maturation of the follicle or
oocyte (Burden et al., 2015).
Over a 17-year period, 319 combined estrous cycles from two mares were
compared and analyzed. In 204 of the 319 cycles, luteolysis was induced with
cloprostenol at varying doses (25 to 1,000 μg). Cloprostenol-manipulated cycles were
more likely (P<0.000) to develop hemorrhagic anovulatory follicles than nonmanipulated cycles, with 25.1% total occurrence of hemorrhagic anovulatory follicles. In
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both mares, the number of multiple dominant follicles, potentially leading to double
ovulations, was higher (P < 0.00 and P= 0.004), respectively for the cloprostenol-treated
cycles when compared to the naturally occurring cycles (Cuervo-Arango and Newcombe,
2009). Small doses (8.75 μg) of cloprostenol have the same luteolytic effect as higher
doses, with no difference in clinical response with the highest incidence recordings of
hemorrhagic anovulatory follicles occurred when cloprostenol was given to mares at
either 625 or 250 μg per dose (Newcombe et al., 2008).

Physiological Effects of PGF2α Administration
Common side effects associated with PGF2α treatment include sweating,
abdominal cramping, and other behaviors associated with colic (Coffman and Pinto,
2016). Listed behaviors, including abdominal cramping, diarrhea, and sweating may
occur for as long as 20 minutes in approximately 10% of mares treated with PGF2α
(McKinnon and Voss, 1993). Low dose (5 mg/mare) administration of the PGF2α analog
Lutalyse may not induce the side effects associated with higher dose (10 mg/mare)
administration in mares (Coffman and Pinto, 2016).
Eight mares received luprostiol (3.75 mg IM), D-cloprostenol (22.5 μg IM), or
saline on day 8 post-ovulation in an alternating order. In both luprostiol and cloprostenol
treatment groups, plasma progesterone concentration decreased to the baseline level
within two days following treatment (P <0.05). Salivary samples were collected to
analyze cortisol levels, heart rate and heart rate variability were measured, skin
temperature was recorded, behavior was monitored, and fecal output was recorded and
scored for consistency. PGF2α treatment significantly increased the concentration of
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salivary cortisol when measured 60 minutes after treatment (P < 0.001). Over time, heart
rate decreased independently of treatment and no changes were recorded in heart rate
variability post-treatment. Administration of PGF2α analogs, either cloprostenol or
luprostiol, is an efficient way of inducing luteolysis with minimal significant side effects,
aside from the increase in salivary cortisol levels (Kuhl et al., 2016b).
When treated with cloprostenol (0.075 mg), 25 mares displayed significant (P
<0.01) increase in intestinal motility. The increase in motility led to diarrhea on a short
term basis, with symptoms subsiding within two hours following onset. Heart rate and
respiratory rate were not significantly altered by administration of cloprostenol (P >
0.05). Sweating and restlessness were also reported in 40-52% of mares involved in the
study (Alcántara et al., 2005).
Because the reproductive cycle of the mare and the timing of physiological events
has such a large impact on the economic success of the equine industry, pregnancy rates
are of utmost concern. After concerns arose that the use and administration of exogenous
prostaglandins may lower conception may lead to lower pregnancy rates in mares,
Metcalf and Thompson (2010) further researched the subject. The 2010 study concluded
that the synchronization and induction of estrus using a prostaglandin analogue,
cloprostenol, did not have a negative impact on pregnancy rate in treated mares (Metcalf
and Thompson, 2010).

Additional Uses of Exogenous Prostaglandins
For mares with delayed uterine involution and endometritis, PGF2α may be given
during the peri-ovulatory period due to its ecbolic effects, though this may lead to luteal
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resurgence (Coffman and Pinto, 2016). In mares treated with PGF2α 24-72 hours postovulation, no decrease in pregnancy rates occurred. During early embryonic growth and
development, mares are capable of maintaining pregnancy with decreased progesterone
concentrations (Newcombe and Cuervo-Arango, 2014).
In mares, an increase in progesterone following a PGFM pulse has not been
recorded. However, it is widely accepted that the equine primary CL undergoes natural
resurgence at day 35 of pregnancy. In pregnant mares, resurgence of the CL is linked to
equine chorionic gonadotropin (eCG) from the endometrial cups and its luteotropic
characteristics. As the size and vascularity of the CL increase, progesterone production
also increases. During CL growth, partial resorption of the corpus hemorrhagicum will
also occur (Ginther and Santos, 2015).
The BAI HUI acupuncture point, in the sacral lumbar space, is commonly used in
the treatment of ovarian conditions in veterinary acupuncture. A 1990s study was
conducted to determine the efficacy of either low or micro doses of PGF2α, when
administered at the BAI HUI acupuncture point. In this study, a micro dose (0.05 mg)
was shown to be equally as effective (P<0.05) as the conventional dose (5.0 mg) when
given to mares in the mid-luteal phase at inducing luteolysis. The BAI HUI acupuncture
point provides an efficient pathway from administration to ovarian effect (Alvarenga et
al., 1998).

Other Protocols Utilized in Breeding Management
Before PGF2α gained recognition as a natural luteolysin, uterine lavage using
saline solution was often implemented for open mares showing signs of a prolonged
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luteal phase in order to gain a return to estrus. This protocol then became a treatment for
mares with a persistent CL. Additionally, intrauterine saline treatment 6 days after
ovulation was shown to shorten the luteal phase of estrous in cycling mares (Coffman and
Pinto, 2016).
The efficacy of using estradiol to synchronize estrus compared to the use of
estradiol and progesterone was evaluated. Mares in group 1 received 50 mg estradiol IM,
and mares in group 2 received 50 mg estradiol in addition to 1.5 g sustained release
progesterone. All mares included in both treatment groups were given 10 mg PGF2α IM
10 days post-treatment. Examinations were performed on all mares via transrectal
ultrasonography on days 1 and 10 post-treatment, then every 1 or 2 days thereafter in
order to determine follicle size. After detection of a follicle larger than 30 mm and uterine
edema, mares were given 0.5 mg histrelin, an analogue of GnRH. After administration of
histrelin, mares were examined ultrasonographically every day until ovulation was
detected. Group 1 mares did not display synchronization of estrus following treatment.
However, mares in group 2 had a much more uniform and synchronized interval to
ovulation of 20.4 + 1.5 days, with a range of 17-22 days. Researchers concluded that
administration of sustained release estradiol and progesterone, followed by administration
of PGF2α 10 days post-treatment, is effective in synchronization of estrus and ovulation,
without daily injections being necessary (Sudderth et al., 2013).
Equine follicle stimulating hormone (eFSH) is often incorporated into
superovulation protocols. A 2010 study (Meyers-Brown et al., 2010) was conducted to
determine whether or not administering varying doses of recombinant equine follicle
stimulating hormone (reFSH) to mares would increase the number of ovulatory follicles
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per cycle, and in turn increase the number of embryos recovered per mare. Because
reFSH can be cloned and synthesized in reliable and consistent quantities, its use over
eFSH is much preferred. As part of the experimental protocol, treatment groups were
given varying doses of eFSH, reFSH, and a combination thereof. The largest number of
ovulations was recorded for the group receiving 12.5 mg eFSH, 0.5 mg reFSH, and 0.65
mg reFSH. The treatment group receiving eFSH and 0.65 mg reFSH had the highest
recorded number of embryos recovered per flush. Also noted in the conclusions was the
similar embryo per ovulation rates between all treatment groups, including the control
group. After data analysis, researchers concluded that administration of reFSH is just as
effective as eFSH, when given to increase the number of follicles greater than 35 mm,
ovulation rates, and the number of embryos recovered per flush (Meyers-Brown et al.,
2010).
In order to simulate a natural PGFM pulse that occurs during luteolysis, oxytocin
(OT) may be administered on day 13 post-ovulation to induce the PGFM pulse. Five
different OT doses (1-10 IU/mare) were used for bolus treatment in the mares. Mares that
received 1.25, 2.5, and 5 IU/100 kg displayed the largest decrease in progesterone within
8 hours of treatment (P < 0.05). Although cyclooxygenase inhibitor treatment with
flunixin meglumine decreased progesterone concentration (P < 0.008), treatment 2 hours
prior to OT administration did not inhibit OT-induced PGFM pulses and the subsequent
decrease in progesterone. A 2 hour OT infusion was sufficient in the study to induce the
PGFM pulse, however the pulse was not stimulated by a single bolus OT treatment. The
OT-stimulated PGFM pulse caused a decrease in progesterone, which was not inhibited
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by flunixin meglumine treatment. In turn, OT has a role in luteolysis in mares, as well as
other species (Santos et al., 2015).
Human chorionic gonadotropin (hCG) dosage rate varies between 1500 to 4000
IU, which an be given either IV or IM. Typical administration of hCG occurs after a
follicle measuring 30 mm or larger is detected. Lower synchronization rates may occur
when hCG is administered on days 1-3 of estrus. Additionally, administration of hCG
may reduce the length of estrous in cycling mares (McKinnon and Voss, 1993).
In the presence of a 35 mm or larger follicle, hCG has been shown to induce
ovulation within 48 hours following treatment. Because hCG is a glycoprotein, antibodies
may develop over the course of repeated treatments, leading to a decrease in the efficacy
of hCG-induced ovulation (Berezowski et al., 2004). Gonadotropin releasing hormone
has been shown to double plasma LH concentrations following administration. GnRH can
be given in order to induce the secretion of FSH and LH, and in turn inducing follicular
growth and development, CL maturation, and ovulation. GnRH may also serve as a
nonantigenic substitute for the administration of hCG to induce ovulation.
Human chorionic gonadotropin is commonly used in Europe for the induction of
ovulation in mares. Mares are often used several times throughout each breeding season;
antibodies against hCG may develop, in turn reducing the efficacy of the treatment
(Newcombe and Cuervo-Arango, 2016). Desorelin does not increase production of hCG
antibodies, but the interovulatory interval for each cycle may increase. Deslorelin is also
less cost efficient per mare when compared to hCG. Suprefact©, (Sanofi; 1 mg/mL), is a
buserelin compound used in human medicine and experimentally used in mares. A large
(5.5 mL), single dose of buserelin was shown to be just as effective at inducing ovulation
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within 48 hours of treatment as hCG. When comparing mares treated with buserelin and
hCG, a larger number of mares (P<0.05) ovulated when given buserelin than hCG.
Because buserelin is effective when given as a single dose and is relatively inexpensive,
its use provides an alternative to multi-dose hCG ovulation induction (Newcombe and
Cuervo-Arango, 2016). Ovulation may be induced efficiently via hCG administration
when given after estrus is induced with luprostiol (Kuhl et al., 2016a).
In 1999, deslorelin (Ovuplant, Fort Dodge Animal Health, Overland Park, KS), a
GnRH agonist, was approved for use in mares when administered as a subcutaneous
controlled-release implant. When compared to hCG, repeated treatment with GnRH has
not been shown to decrease efficacy of ovulation induction. In mares with a 30 mm or
larger follicle, 88% of mares were shown to ovulate within the 48 hours following
treatment when induced with Ovuplant; however Ovuplant is not available for use in
mares in the United States (Berezowski et al., 2004).
Although Ovuplant is not available for use, an injectable deslorelin analog,
Sucromate ™ (Thorn BioScience, Lexington, KY) has been approved by the FDA for use
in the United States. A 2012 study compared the efficacy of delsorelin to induce
ovulation in mares when compared to hCG. After detection of a follicle measuring 35
mm or larger, 1.0 mL of Sucromate was administered intramuscularly. Approximately
89% of mares ovulated without 48 hours following treatment, a rate similar to that seen
following administration of hCG. The study concluded that Sucromate, injectable
deslorelin, is an effective method of inducing ovulation in mares (Ferris et al., 2012).
Although less common, fractionated coconut oil can be implemented in
intrauterine infusion protocols for mares. Plant oil infusion has been shown to be a safe,
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reversible, and inexpensive method of lengthening the luteal phase of the estrous cycle
when administered to mares on day 10 of the cycle. Diel de Amorim et al. (2016)
hypothesized that administration of intrauterine coconut oil infusion would lead to higher
serum progesterone levels at the time of luteolysis when compared to untreated mares.
For the study, half of the mares (n=5) were administered 1.0 mL fractionated coconut oil
infused into the uterus using an artificial semination pipette on day 10 of the estrous
cycle; the remaining mares (n=5) were given 0.5 mL fractionated coconut oil infused into
the uterus using an embryo transfer gun on day 10 of the estrous cycle. Intrauterine
administration of 1.0 mL fractionated coconut oil did not lengthen the luteal phase in the
treated mares, and lowered diestrus progesterone levels (P<0.05). In a 2013 preliminary
study comparing sesame, coconut, and fractionated coconut oils, the same results were
found; progesterone levels decreased at the time of luteolysis, with a faster return to
estrus (Diel de Armorim et al., 2016).
Flunixin meglumine (FM), a PGF2α inhibitor, can be administered in order to
analyze the occurrence of prolonged luteal activity in treated mares. As part of Santos et
al.’s study (2013), FM was administered every 8 hours at 1.0 mg/kg body weight on days
14-16.7. PGF2α metabolite concentration over an 8 hour time period was lower in the
mares treated with FM on day 14 post-ovulation, compared to the untreated mares. The
interval from ovulation to a decrease in progesterone and the end of luteolysis (P4<1
ng/mL) was prolonged by approximately 1 day in the mares treated with FM. This study
confirmed that PGF2α synthesis inhibition effects luteolysis, and if inhibition occurs at the
time luteolysis is expected, prolonged luteal activity may be present (Santos et al., 2013).
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Figure 1. Stages of the estrous cycle (Mottershead, 2001).
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Figure 2. Endocrinology of the estrous cycle (Mottershead, 2001).
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Figure 3. Plasma progesterone levels (ng/mL) in pregnant vs non-pregnant mares
(McKinnon and Voss, 1993)
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MATERIALS AND METHODS

IACUC Compliance
This project was funded by the USDA NLGCA Capacity Building Grant and
approved by IACUC Protocol 15-025.0-B. Research was conducted at the Missouri State
University Darr Agriculture Center in Springfield, Missouri. Research began in May
2017 and concluded in July 2017. Eleven Quarter Horse mares (468- 572 kg, 7-23 years
old) were used for the study.

Experimental Design and Procedures
Mares were teased using a teaser stallion, and teasing scores (T0-T4) were
assessed daily. A description of criteria for each teasing score is as follows:
0

Mare shows no signs of receptivity; possibly some aggression toward the
stallion- striking, kicking, squealing, etc.

1

No aggression toward the stallion.

2

Some interest; mare may approach the stallion and exhibit some winking
of the vulva and tail raising.

3

More interest, tail raising, squatting, urination.

4

Intense interest; turns hindquarters toward the stallion with continuous
winking and frequent urination.

(Coleman and Powell, 2004)
Once a T3 teasing score was detected, rectal palpation and ultrasound were both
performed. A digital ultrasound display and transrectal probe were used in order to
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perform ultrasound, and follicular diameter was measured (mm) during each
examination. Individual record books were utilized for each mare in order to record
teasing scores as well as follicular growth and location (right or left ovary) of each
follicle. When an ovarian follicle measured 30 mm or larger, mares were examined daily,
including rectal palpation, ultrasound, and measurement of follicles, until ovulation was
detected.
In a crossover design, each mare was subjected to all treatments. Mares were
assigned to one of three treatment groups. Treatment protocols were as follows: treatment
1- PGF2α administered once on day 6 post-ovulation; treatment 2- PGF2α administered
twice daily on days 0, 1, and 2, then once on days 3 and 4 post-ovulation; treatment 3PGF2α administered twice daily on day 2, then once on days 3 and 4 post-ovulation.
Dinoprost tromethamine (Lutalyse ®) was administered at a dosage rate of 1 mg/45.5 kg
body weight, and concentrated in a 5 mg/mL solution. Lutalyse was administered IM to
each mare for each dose of the assigned treatment. To ensure that each mare received a
full 1.0 mL of Lutalyse for each dose of each treatment, 1.1 mL was administered per
injection. Treatment 1 was used as a control protocol; a single injection of PGF2α is
typically administered to induce luteolysis. Treatments 2 and 3 were included in the study
to repeat the protocols of a previous studies utilizing higher dosage rates of Lutalyse
(Coffman et al., 2014; Pinto et al., 2014).
In order to track fluctuations in P4 levels for each mare, blood samples were
collected using jugular venipuncture on days 3 and 6 post-ovulation. Blood was collected
using 6.0 mL syringes with 18.0 gauge needles. Samples were transferred to 10 mL BD
Vacutainer® vials, then set in test-tube rack in order to clot, for approximately ten
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minutes. Once coagulation occurred, vials were centrifuged for five minutes in order to
separate serum from the clot. Serum was removed from the vials using 3 mL disposable
pipettes, and placed in 1.5 mL microcentrifuge vials. Each 1.5 mL vial with serum was
labeled with the date and the identifying number of the horse, then frozen. Progesterone
ELISA kits ADI-900-011 and ADI-901-011 (Enzo Life Sciences) were used to analyze
samples by Northcutt Laboratories in Middletown, Missouri. The assay was run at a
dilution rate of 1 to 125, 1 to 250, or 1 to 400 in order to reach a 50% binding rate for
each sample. Results were recorded in picograms per milliliter then converted to
nanograms per milliliter for analysis in this study.

Statistics
Minitab 17 (Minitab Inc., State College, PA) software was used for data analysis,
with significant difference set at p = 0.05. One-way ANOVA and the Tukey Method
pairwise comparisons were used in order to analyze the intervals from ovulation to
ovulation and treatment to ovulation between treatment groups.
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RESULTS AND DISCUSSION

Data Analysis
The age and approximate weight of mares used in the study were recorded in T1.
The order of treatments received for each mare in the study were random, and recorded in
T2. Mean intervals from ovulation to ovulation for treatments 1, 2, and 3 were 14.8 d ±
3.1, 12.9 d ± 6.3 d and 14.3 d ± 1.4 respectively, and recorded in T3. Mean intervals from
first day of treatment to ovulation for treatments 1, 2, and 3 were 9.8 d ± 2.0, 12.9 d ±
6.3, and 12.6 d ±1.7, and recorded in T4. ANOVA analysis of these variables revealed no
significant differences (p>0.05).
Mean intervals from ovulation to the detection of a 30+mm follicle for treatments
1, 2, and 3 were 13.2 d ± 2.2, 9.2 d ± 3.0, and 12.0 d ± 2.2 respectively, and recorded in
T5. Mean intervals from the first day of treatment to the detection of a 30+ mm follicle
for treatments 1, 2, and 3 were 8.1 d ± 1.1, 9.5 d ± 2.7, and 10.3 d ± 1.7 respectively, and
recorded in T6. Mean intervals from ovulation to the display of estrus (teasing score ≥
T3) for treatments 1, 2, and 3 were 10.6 d ± 4.4, 6.9 d ± 2.6, and 10.3 d ± 6.8
respectively, and recorded in T7. Mean intervals from the first day of treatment to the
display of estrus (teasing score ≥ T3) for treatments 1, 2, and 3 were 5.9 d ± 3.6, 8.1 d ±
5.2, and 6.0 d ± 3.9 respectively, and recorded in T8.
Mean intervals from ovulation to ovulation for treatments 1, 2, and 3 with outliers
removed (n=1) from analysis were 14.8 d ± 3.1, 11.1 d ± 3.1, and 14.3 d ± 1.4
respectively. Under Tukey Method pairwise comparison, treatment 2 was significantly
different from treatments 1 and 3 (p= 0.013). Mean intervals from first day of treatment
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to ovulation for treatments 1, 2, and 3 with outliers removed from analysis were 9.8 d ±
2.0, 11.1 d ± 3.1, and 12.6 d ± 1.7 respectively. Treatments 2 and 3 were significantly
different from treatment 1, though not significantly different from each other (p= 0.052).
Mean plasma progesterone levels on day 3 post-ovulation for treatments 1, 2, and
3 were 6.0 d ± 2.5, 4.5 d ± 1.9, and 6.4 d ± 1.6 respectively, and recorded in T9. Mean
plasma progesterone levels on day 6 post-ovulation for treatments 1, 2, and 3 were 10.9 d
± 10.1, 3.9 d ± 2.0, and 3.9 d ± 1.9 respectively, and recorded in T10. Plasma
progesterone levels were not statistically difference between treatments from day 3 to day
6 post-ovulation. However, progesterone levels numerically increased within treatment 1
from day 3 to day 6 post-ovulation. Progesterone levels decreased between days 3 and 6
post- ovulation for treatments 2 and 3.

Data Limitations
Statistical outliers may have contributed to a lack of significance in results. When
One-way ANOVA and Tukey Method analysis were performed removing statistical
outliers, some results of the study became statistically significant.
Plasma progesterone immuno-assay test levels were not all attained at the desired
50% binding rate. Values recorded at less than 50% binding may be less accurate, and
may have contributed to statistical skew and lack of significance.

Discussion
Although results were not significantly different, these findings agree with
previous studies (Coffman et al., 2014; Pinto et al., 2014) utilizing a dose of 10 mg
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dinoprost tromethamine. On treatment 2, one mare displayed estrus and maintained a
follicle greater than 30 mm for 13 days, and had an intra-ovulatory interval of 29 days.
On treatment 3, one mare failed to return to estrus or develop a dominant follicle
measuring larger than 30 mm. Statistical outliers as described may have contributed to a
lack of significance in statistical analysis; however results of treatment 2 became
significantly different from treatments 1 and 3 with outliers removed.
Previous studies have utilized administration of hCG following PGF2α to ensure
timely ovulations. Mares develop antibodies against hCG with repeated treatment, in turn
decreasing efficacy rates. Because mares were used in a crossover design with three
subsequent estrous cycles, hCG was not administered to mares following each PGF2α
protocol. If hCG or Delsorelin had been administered to mares along with PGF2α for
each treatment protocol, evaluation of the efficacy of low-dose serial administration of
PGF2α might have been compromised.
Mares in this study were characterized by a wide range in age, as seen in Table 1.
A more uniform age range for mares used in subsequent studies may provide more
consistent results, potentially with statistical significance. In this study, maiden mares
were used alongside broodmares. Increasing uniformity of mares used by decreasing the
range in ages may have improved results of the study. Additionally, a larger sample size
would have most likely increased the consistency of results seen in the study.
Plasma progesterone levels were analyzed in order to track changes throughout
the estrous cycle for each mare for each given treatment. Also, plasma progesterone
levels were evaluated as a measure of luteal tissue development for each treatment. If
serial low-dose administration of PGF2α had prevented luteal tissue development during
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the early diestrus period, progesterone levels should have verified the absence of a
functional CL. However, plasma progesterone results were not significantly different
among treatment groups. Most serum samples were run at varying dilutions in attempts to
reach a minimum 50% binding rate for each sample. However, not all samples were rerun to obtain a higher binding rate, as opposed to other samples which were re-run two
and three times. With binding rates as low as 11.1% and as high as 91.2%, a wide range
of plasma progesterone levels were recorded. Because of such a wide range in recorded
results, statistical analysis of progesterone levels showed no significance. If serum
samples had reached a more uniform range of percent antibody binding rate, results may
have become significant and supported the hypothesized prevention of luteal
development.
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Table 1. Ages (years) and weights (kg) of Quarter Horse mares treated with serial
injections of PGF2α
Mare
Age
Weight
1

22

558

2

6

457

3

22

564

4

6

395

5

18

518

6

10

498

7

15

505

8

12

573

9

15

493

10

24

470

11

12

550
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Table 2. Order of treatment protocol received for mares treated with serial injections of
PGF2α
Mare
Treatment 1*
Treatment 2**
Treatment 3***
1

A

B

C

2

C

A

B

3

C

A

B

4

A

C

B

5

C

A

B

6

B

A

C

7

B

C

A

8

C

A

B

9

C

B

A

10

B

A

C

11

A

B

C

A- First treatment
B- Second treatment
C- Third treatment
*
- One injection of PGF2α 6 d post-ovulation
**
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
***
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
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Table 3. Mean number of days recorded from ovulation to ovulation for mares treated
with serial PGF2α injections, by treatment
Treatment
Mean
SD
Range
Covariance
1a

14.8

3.1

9-18

8.76

2b

12.9

6.3

4-29

36.29

3c

14.3

1.4

12-17

1.78

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b

Table 4. Mean number of days recorded from first day of treatment to ovulation for
mares treated with serial injections of PGF2α, by treatment
Treatment
Mean
SD
Range
Covariance
1a

9.8

2.0

5-12

3.76

2b

12.9

6.3

4-29

36.29

3c

12.6

1.7

10-16

2.47

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b

38

Table 5. Mean number of days recorded from ovulation to detection of a 30+ mm follicle
for mares treated with serial injections of PGF2α, by treatment
Treatment
Mean
SD
Range
Covariance

1a

13.2

2.2

9-16

4.17

2b

9.2

3.0

3-13

8.16

3c

12.0

2.0

9-15

3.56

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b

Table 6. Mean number of days recorded from first day of treatment to detection of a 30+
mm follicle for mares treated with serial injections of PGF2α, by treatment
Treatment
Mean
SD
Range
Covariance

1a

8.1

1.1

7-10

1.11

2b

9.5

2.7

3-13

6.65

3c

10.3

1.7

7-13

2.44

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b
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Table 7. Mean number of days recorded from ovulation to detection of the onset of estrus
(teasing score ≥ T3) for mares treated with serial injections of PGF2α, by treatment
Treatment
Mean
SD
Range
Covariance

1a

10.6

4.4

1-16

17.64

2b

6.9

2.6

3-11

5.86

3c

10.3

6.8

4-24

39.35

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b

Table 8. Mean number of days recorded from first day of treatment to detection of the
onset of estrus (teasing score ≥ T3) for mares treated with serial injections of PGF2α, by
treatment
Treatment
Mean
SD
Range
Covariance

1a

5.9

3.6

0-12

11.49

2b

8.1

5.2

3-20

23.88

3c

6.0

3.9

1-12

12.67

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b
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Table 9. Mean plasma progesterone concentrations on day 3 post-ovulation for mares
treated with serial injections of PGF2α, by treatment (ng/mL)
Treatment
Mean
SD
Range
Covariance
1a

6.0

2.5

3.3-9.1

4.57

2b

4.5

1.9

2.6-7.0

3.07

3c

6.4

1.6

3.7-8.9

2.39

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b

Table 10. Mean plasma progesterone concentrations on day 6 post-ovulation for mares
treated with serial injections of PGF2α, by treatment (ng/mL)
Treatment
Mean
SD
Range
Covariance
1a

10.9

10.1

2.7-34.2

4.62

2b

3.9

2.0

1.6-7.0

3.33

3c

3.9

1.9

1.8-6.2

7.29

a

- One injection of PGF2α 6 d post-ovulation
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
b
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CONCLUSIONS

In this study, no significant difference was shown between single and multipledose PGF2α treatment protocols used to prevent luteal development and shorten the
interval to ovulation in cycling mares. However, low-dose administration of PGF2α may
provide an alternative to the 10.0 mg dose normally given. Low-dose administration of
PGF2α during the early diestrus period of the estrous cycle has the potential to improve
the efficiency of breeding programs in terms of total injections administered and intensity
of the protocol.
Previous studies implementing a single-dose treatment as a control have
administered PGF2α as a single injection between days 5 and 10 post-ovulation, during
the mid-diestrus period. However, the CL has been shown to be responsive to PGF2α
when the CL reaches maturity at 5 days post-ovulation; therefore the single dose
treatment used in this study administered one injection of PGF2α on day 6 post-ovulation.
Results of the study were similar to previous studies implementing the protocol
used for Treatment 3. Treatment 3 could be utilized by owners or breeding facility
professionals if an ovulation goes undetected. However, if the exact date of ovulation is
unknown, treatment with serial PGF2α may not be as effective at shortening the interval to
ovulation when the treatment is started a few days later. In terms of efficacy, PGF2α
treatment is most successful when ovulation can be tracked and recorded, and a treatment
protocol implemented accordingly.
Although overall results were not significant, the statistical analysis with outliers
removed supports the hypothesis that serial administration of PGF2α may prevent luteal

42

development and may provide a means of faster manipulation of the mare in order to
successfully complete time-sensitive breedings and embryo transfer programs.
Breeding facilities often charge owners for individual daily expenses of
management- boarding, feed and supplements, palpation, ultrasound, injections,
insemination, pregnancy checks, and more. With high costs associated with long-term
boarding at breeding facilities, shortening the interval to ovulation by even 2 days could
provide financial savings for equine owners. Example costs associated with daily mare
care and management at a breeding facility are as follows:
Description

Cost

Dry Mare Board

$12.00-20.00/day

Dry Mare Board, Under Lights

$17.00-20.00/day

Private Care Board

$20.00-29.00/day

Special Care Board

$20.00-29.00/day

Palpation

$15.00-16.00 each

Palpation and Breeding

$10.00-25.00-each

Ultrasound

$40.00-65.00/breeding season

Progesterone Assay

$30.00-35.00 each

Regumate

$3.50-6.00/day

(Granada Farms, 2017; Lazy E Ranch, 2017; Oswood Stallion Station, 2017)
Lutalyse, when administered at 1.1 mL per dose, is approximately $0.64 per
injection. With minimal daily mare care starting approximately $17 per day, utilization of
a low-dose serial PGF2α treatment protocol may provide significant savings. At a lowcost, serial administration of PGF2α may provide a relatively inexpensive method of
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shortening the interval to ovulation. The estimated costs per treatment protocol is
described as follows:
Description

Cost

1.0 mL (5.0 mg) Lutalyse

$0.57-0.67/dose

2.0 mL (10.0 mg) Lutalyse

$1.15-1.36/dose

Treatment 1 Protocola

$0.57-0.67/mare

Treatment 2 Protocolb

$4.56-5.36/mare

Treatment 3 Protocolc

$2.28-2.68/mare

(Valley Vet Supply, 2017)
a
- One injection of PGF2α 6 d post-ovulation
b
- Injections of PGF2α twice daily on d 0,1, and 2, then once daily on d 3 and 4 postovulation
c
- Injections of PGF2α twice daily on d 2, then once daily on d 3 and 4 post-ovulation
Further research is needed to determine the effects of serial low-dose
administration of a PGF2α analog on the interval to ovulation in mares.
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